BiotechTube

E2609 + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease, Dementia, Alzheimer Type

Trial Timeline

Nov 26, 2014 → Dec 20, 2019

NCT ID
NCT02322021

About E2609 + Placebo

E2609 + Placebo is a phase 2 stage product being developed by Eisai for Alzheimer Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02322021. Target conditions include Alzheimer Disease, Dementia, Alzheimer Type.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)
✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
✅DonepezilEisaiApproved
✅DONEPEZIL HYDROCHLORIDEEisaiApproved
✅Donepezil HCLEisaiApproved
✅Donepezil HClEisaiApproved
✅Donepezil HydrochlorideEisaiApproved
✅AriceptEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT03055962Phase 1Completed
NCT02322021Phase 2Terminated
NCT02207790Phase 1Completed
NCT01511783Phase 1Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
Zagotenemab + PlaceboEli LillyPhase 2
35
Donanemab + Placebo + LY3202626Eli LillyPhase 2
35
Donanemab + PlaceboEli LillyPhase 3
47
GSK4527226AlectorPhase 2
29
AL002 + PlaceboAlectorPhase 2
25
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
donanemabEli LillyPhase 2
35
ATH-1017LeonaBioPhase 2/3
20
ATH-1017 + PlaceboLeonaBioPhase 2/3
28
ATH-1017 + PlaceboLeonaBioPhase 2
25
NDX-1017 + PlaceboLeonaBioPhase 1
19
simufilamCassava SciencesPhase 2
17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
19